TY - JOUR
T1 - Solid phase synthesis and biological activity of mast cell degranulating (MCD) peptide
T2 - a component of bee venom
AU - BUKU, ANGELIKI
AU - BLANDINA, PATRIZIO
AU - BIRR, CHRISTIAN
AU - GAZIS, DIANA
PY - 1989/2
Y1 - 1989/2
N2 - Mast cell degranulating (MCD) peptide, a 22 amino acid residue basic peptide from bee venom, was synthesized by stepwise solid phase synthesis on a benzhydrylamine resin support. Nα‐t‐butyloxycarbonyl and benzyl type side chain protection was used. The two disulfide bridges were formed selectively by using S‐acetamidomethyl protection for the cysteine residues in positions 5 and 19 and S‐methylbenzyl protection for the cysteine residues in positions 3 and 15. Crude synthetic MCD peptide was obtained following deprotection and cleavage from the resin by the low/high HF method. The peptide was isolated in pure form by ion exchange chromatography and gel filtration. The final product has physical, chemical, and biological properties identical with those reported for the natural product. The synthetic strategy utilized for MCD peptide will facilitate the availability of structurally similar analogs for evaluating antihistaminic and anti‐inflammatory activities.
AB - Mast cell degranulating (MCD) peptide, a 22 amino acid residue basic peptide from bee venom, was synthesized by stepwise solid phase synthesis on a benzhydrylamine resin support. Nα‐t‐butyloxycarbonyl and benzyl type side chain protection was used. The two disulfide bridges were formed selectively by using S‐acetamidomethyl protection for the cysteine residues in positions 5 and 19 and S‐methylbenzyl protection for the cysteine residues in positions 3 and 15. Crude synthetic MCD peptide was obtained following deprotection and cleavage from the resin by the low/high HF method. The peptide was isolated in pure form by ion exchange chromatography and gel filtration. The final product has physical, chemical, and biological properties identical with those reported for the natural product. The synthetic strategy utilized for MCD peptide will facilitate the availability of structurally similar analogs for evaluating antihistaminic and anti‐inflammatory activities.
KW - MCD‐peptide
KW - blood pressure decrease
KW - histamine release
KW - low‐high HF
KW - solid phase synthesis
UR - http://www.scopus.com/inward/record.url?scp=0024549668&partnerID=8YFLogxK
U2 - 10.1111/j.1399-3011.1989.tb00192.x
DO - 10.1111/j.1399-3011.1989.tb00192.x
M3 - Article
C2 - 2468626
AN - SCOPUS:0024549668
SN - 0367-8377
VL - 33
SP - 86
EP - 93
JO - International Journal of Peptide and Protein Research
JF - International Journal of Peptide and Protein Research
IS - 2
ER -